Idera Pharma: Wedbush PacGrow Healthcare Conference (Idera Pharmaceuticals, Inc) - Aug 21, 2016 - Anticipated dose escalation data from P1/2 trial (NCT02092909) in Waldenstrom's macroglobulinemia and P1/2 trial (NCT02252146) in DLBCL in H1 2017
Anticipated P1/2 data • Diffuse Large B Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|